Alerts will be sent to your verified email
Verify Email
BAFNAPH
|
Bafna Pharma
|
Jenburkt Pharma
|
Haleos Labs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
0.0 | 18.49 % | 9.86 % |
|
5yr average Equity Multiplier
|
3.77 | 1.17 | 2.28 |
|
5yr Average Asset Turnover Ratio
|
0.42 | 0.88 | 0.85 |
|
5yr Avg Net Profit Margin
|
-36.55 % | 18.1 % | 4.95 % |
|
Price to Book
|
9.19 | 2.53 | 1.98 |
|
P/E
|
42.3 | 14.33 | 24.45 |
|
5yr Avg Cash Conversion Cycle
|
0.18 Days | -32.02 Days | -6.07 Days |
|
Inventory Days
|
87.65 Days | 24.72 Days | 78.84 Days |
|
Days Receivable
|
132.64 Days | 48.38 Days | 56.81 Days |
|
Days Payable
|
210.48 Days | 82.6 Days | 142.69 Days |
|
5yr Average Interest Coverage Ratio
|
-5.68 | 87.2 | 4.18 |
|
5yr Avg ROCE
|
-11.61 % | 24.44 % | 11.01 % |
|
5yr Avg Operating Profit Margin
|
-21.98 % | 22.46 % | 10.73 % |
|
5 yr average Debt to Equity
|
1.41 | 0.02 | 0.52 |
|
5yr CAGR Net Profit
|
12.0 % | 14.21 % | 8.2 % |
|
5yr Average Return on Assets
|
-16.11 % | 15.8 % | 4.32 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 46.64 % | 72.11 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-15.0 % | -0.92 % | 1.79 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Bafna Pharma
|
Jenburkt Pharma
|
Haleos Labs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|